Welcome to our dedicated page for Dice Therapeutics news (Ticker: DICE), a resource for investors and traders seeking the latest updates and insights on Dice Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dice Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dice Therapeutics's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
DICE Therapeutics, a biopharmaceutical company traded on Nasdaq under the symbol DICE, announced its participation in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, scheduled for March 30, 2023, at 4:00 p.m. ET. The event will focus on DICE's novel oral therapeutic candidates targeting chronic diseases in immunology, utilizing its proprietary DELSCAPE technology platform. A live and archived webcast will be available for 90 days post-event on the company's website. DICE is dedicated to developing effective oral treatments against key immunology targets like IL-17 and integrin α4ß7, aiming to match systemic biologics' potency.
DICE Therapeutics, Inc. (Nasdaq: DICE) announced significant advancements in its clinical pipeline, highlighted by the FDA's clearance of the IND application for its lead oral IL-17 antagonist, DC-806. A global Phase 2b trial for DC-806 in psoriasis is set to begin in 1H 2023. Additionally, the company has initiated a Phase 1 trial for its second oral IL-17 antagonist, DC-853, with topline data expected in 2H 2023. As of December 31, 2022, DICE reported a robust cash position of $574.2 million, projected to fund operations through 2026 and important clinical milestones.
DICE Therapeutics, Inc. (Nasdaq: DICE) announced that data from its Phase 1 clinical trial of DC-806 will be presented at the 2023 American Academy of Dermatology Annual Meeting on March 18, 2023. DC-806 is a small molecule antagonist targeting IL-17, which plays a crucial role in psoriasis. This presentation aims to showcase the proof-of-concept findings for treating mild-to-moderate psoriasis. DICE plans to advance DC-806 into a Phase 2b clinical trial in the first half of 2023, following positive Phase 1 results. The company focuses on developing oral therapeutics for chronic conditions, including psoriasis, inflammatory bowel disease, and idiopathic pulmonary fibrosis.
DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company specializing in oral therapeutics for chronic diseases, announced participation in two major investor conferences. The SVB Securities Global Biopharma Conference features a fireside chat on February 14, 2023, at 2:20 p.m. ET, followed by the 43rd Annual Cowen Healthcare Conference dermatology panel on March 7, 2023, at 12:50 p.m. ET. Live and archived webcasts of these presentations will be available for 90 days on the company’s website. DICE focuses on developing novel oral candidates targeting immunology, aiming for comparable effectiveness to existing biologics.
FAQ
What is the market cap of Dice Therapeutics (DICE)?
